Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy

Conclusions: Adefovir plus lamivudine is an effective alternative of tenofovir plus lamivudine in long-term HBV treatment outcome in HIV/HBV coinfected patients.
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research

Related Links:

Condition:   Hepatitis B, Chronic Interventions:   Drug: JNJ-73763989;   Drug: JNJ-56136379;   Drug: Placebo for JNJ-73763989;   Drug: Placebo for JNJ-56136379;   Drug: Entecavir (ETV) monohydrate;   Drug: Tenofovir disoproxil fumarate (TDF);   Drug: Tenofovir alafenamide (TAF) Sponsor:   Janssen Research & Development, LLC Not yet recruiting
Source: - Category: Research Source Type: clinical trials
AbstractPurposeTo determine the diagnostic performance of intravoxel incoherent motion (IVIM) parameters to predict tumor recurrence after hepatectomy in patients with hepatitis B virus (HBV) –related hepatocellular carcinoma (HCC).Materials and methodsOne hundred and fifty-seven patients (mean age 52.54  ± 11.32 years, 87% male) with surgically and pathologically confirmed HCC were included. Regions of interests were drawn including the tumors by two independent radiologists. ADC and IVIM-derived parameters (true diffusion coefficient [D]; pseudodiffusion coefficient [D*]; pseudodiffusion f...
Source: European Radiology - Category: Radiology Source Type: research
Publication date: Available online 15 October 2019Source: Meta GeneAuthor(s): Nevin Karakus, Fazilet Duygu, Umut Say Coskun, Ayfer Atay, Serbulent YigitAbstractHepatitis B is a major health problem in Turkey as it is all over the world. Therefore, it is noteworthy to understand the genetic background of hepatitis B virus (HBV)-infection. In order to investigate the effect of the PON1 gene in different clinical conditions of HBV infection, we analyzed common Q192R (rs662) and L55 M (rs854560) polymorphisms in HBV-infected individuals through PCR and RFLP technics. The present study involved 59 HBV carriers (chronic inacti...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
This review provides an overview of the current evidence supporting the use of combination therapies for chronic HBV, summarizing expert consensus on a roadmap to attain functional cure.Journal of Viral Hepatitis
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
pinyo Hongeng More than 350 million people worldwide have been persistently infected with the hepatitis B virus (HBV). Chronic HBV infection could advance toward liver cirrhosis and hepatocellular carcinoma. The intervention with prophylactic vaccine and conventional treatment could suppress HBV, but could not completely eradicate it. The major obstacle for investigating curative antiviral drugs are the incompetence of hepatocyte models that should have closely imitated natural human infection. Here, we demonstrated that an immortalized hepatocyte-like cell line (imHC) could accommodate for over 30 days the entire l...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Publication date: Available online 14 October 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Wei Hou, Zhixiao Huo, Yanan Du, Cindy Wang, Wing-Kin SynSummaryObjectivesSimultaneous positivity for both hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-HBs) is an atypical serological profile in chronic hepatitis B (CHB) patients. The exact mechanisms underlying the uncommon profile remains unclear. The aim of this study was to analyze the characteristics of amino acid substitutions within the “a” determinant region in a large cohort of CHB patients with coexistence of ...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
Updated Date: Tue, 15 Oct 2019 00:00:00 EDT
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Updated Date: Tue, 15 Oct 2019 00:00:00 EDT
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
Conclusions: LysoPC (24:0) could distinguished HCC from HBG, and 8 SCMs distinguished HCC from healthy controls. LysoPC and other metabolites have the potential to serve as non-invasive biomarkers for HBV related AFP– and AFP+ HCC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Hepatitis | Hepatitis B | India Health | Microbiology | Statistics | Study | Tropical Medicine | Viread